Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up

ABSTRACT

The Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI) study is a longitudinal prospective cohort of 50 participants at a single institution in Buenos Aires, Argentina. Longitudinal assessments on a neuropsychological test battery were performed on 15 controls, 24 mild cognitive impairment (MCI) patients and 12 Alzheimer's disease (AD) dementia patients. In our study population, there was a high prevalence of positive AD biomarkers in the AD group, 92.3% (12/13); and a low prevalence in the normal controls, 20%; almost half (48%) of the patients diagnosed with MCI had positive amyloid detection. After a one year, the significant differences found at baseline on neuropsychological testing were similar at the follow-up assessment even though the AD group had significantly altered its functional performance (FAQ and CDR). The exception was semantic fluency, which showed greater impairment between the AD group and MCI and normal controls respectively. For these tests, the addition of AD biomarkers as a variable did not significantly alter the variations previously found for the established clinical group's model. Finally, the one-year conversion rate to dementia was 20% in the MCI cohort.

RESUMO

El estudio de Argentina-Alzheimer's Disease Neuroimaging Initiative (Arg-ADNI) es una cohorte prospectiva de 50 pacientes seguidos en una misma institución. Fueron evaluados cognitivamente 15 controles normales (CN), 24 sujetos con deterioro cognitivo leve (DCL) y 12 con demencia tipo Alzheimer (DTA) leve. En los DTA, 92,3% tuvieron biomarcadores positivos para Alzheimer y 20% en los CN. Casi la mitad de los DCL presentaron biomarcadores positivos. Después de un año de seguimiento, la diferencias significativas halladas en la visita de inicio en las pruebas cognitivas fueron similares al año aunque los DTA tuvieron empeoramiento funcional medido en el FAQ y CDR. La excepción fue la fluencia semántica, la cual mostró mayor declinación entre DTA y los demás grupos. La incorporación de los biomarcadores como variable no alteró significativamente los hallazgos de grupo. La tasa de conversión a demencia anual fue del 20%.

Keywords:

Alzheimer's disease - cognitive dysfunction - biomarkers - neuroimaging

Palabras-clave:

enfermedad de Alzheimer - disfunción cognitiva - biomarcadores - neuroimagen

Support

FLENI Foundation supported this work.

Publikationsverlauf

Eingereicht: 19. September 2017

Angenommen: 08. Januar 2018

Artikel online veröffentlicht:
28. August 2023

• References

• 1 Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007 Jul;3(3):186-91. https://doi.org/10.1016/j.jalz.2007.04.381
• 2 Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's Disease in the United States and the public health impact of delaying disease onset. 1998;88(9):1337-42. https://doi.org/10.2105/AJPH.88.9.1337
• 3 World Health Organization – WHO. Dementia: a public health priority. Geneva: World Health Organization; 2012.
• 4 Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008 Sep;7(9):812-26. https://doi.org/10.1016/S1474-4422(08)70169-8
• 5 Dementia C. Question- FA, Activities F. New lessons from the Alzheimer's Disease neuroimaging initiative. 2011;68(1):19-21. https://doi.org/10.1001/archneurol.2010.344
• 6 Russo MJ, Gustafson D, Vázquez S, Surace E, Guinjoan S, Allegri RF et al. Creation of the Argentina-Alzheimer's disease neuroimaging initiative. Alzheimer's Dement. 2014 Feb;10(1):S84-7. https://doi.org/10.1016/j.jalz.2013.09.015.
• 7 Hachinski V, Oveisgharan S, Romney AK, Shankle WR. Optimizing the Hachinski Ischemic Scale. Arch Neurol. 2012 Feb;69(2):169-75. https://doi.org/10.1001/archneurol.2011.16988.
• 8 Sheikh J, Yesavage J. Recent evidence and development of a shorter version, in clinical gerontology: a guide to assessment and intervention.d Brink T L, editor. Título do livro. New York, NY: The Haworth Press; 1986. p. 165-73.
• 9 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. https://doi.org/10.1016/0022-3956(75)90026-6.
• 10 Allegri RF, Ollari JA, Mangone CA, Arizaga RL, De Pascale A, Pellegrini M et al. El “Mini-Mental State Examination” en la Argentina: instrucciones para su administración. Rev Neurol Argent. 1999;24(1):31-5.
• 11 Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566-72. https://doi.org/10.1192/bjp.140.6.566
• 12 Wechsler D. Wechsler memory scale. 3rd ed. San Antonio: TX Psychol; 1997.
• 13 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939-44. https://doi.org/10.1212/WNL.34.7.939
• 14 Peña-Casanova J, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, Sol JM et al. [Adaptation and normalization of the Alzheimer's disease Assessment Scale for Spain (NORMACODEM) (II)]. Neurol (Barcelona, Spain). 1997 Feb;12(2):69-77. Spanish.
• 15 Mangone C, De Pascale A, Gigena V, Sanguinetti R, Bauman P, Pereyra S et al. Escala de evaluación para enfermedad de Alzheimer: adaptación ala lengua castellana, confiabilidad interexaminadores y en retesteo seriado. Rev Neurol Argent. 1995;20(2):31-40.
• 16 Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Https://doi.org/10.1111/j.1532-5415.2005.53221.x
• 17 Delgado C, Araneda A BM. Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years. Neurologia. 2017;S0213-4853((17)):30102-0. htps://doi.orh/10.1016/j.nrl.2017.01.013
• 18 Gigena VM, Mangone CA. El test del reloj: una evaluación cognitiva rápida y sensible al deterioro incipiente. Rev Neurol Argent. 1993;18:35-42.
• 19 Rey. Rey Auditory Verbal Learning Test. RAVLT; L'examen Clinique En Psychologie. Paris: Presses Universitaires de France. 1964.
• 20 Burin D, Ramenzoni VA. Evaluación neuropsicológica del envejecimiento: normas según edad y nivel de educación. Rev Neurol Argent. 2003;28(3):149-52.
• 21 Serrano C, Allegri RF, Drake M, Butman J, Harris P, Nagle C et al. [A shortened form of the Spanish Boston naming test: a useful tool for the diagnosis of Alzheimer's disease]. Rev Neurol. 2001Jan;33(7):624-7. Spanish.
• 22 Butman J, Allegri RF, Harris PD. Fluencia verbal en español: datos normativos en Argentina. Med (Buenos Aires). 2000;60(6):561-4.
• 23 Tombaugh TN. Trail making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004 Mar;19(2):203-14. https://doi.org/10.1016/S0887-6177(03)00039-8
• 24 Arango-Lasprilla JC, Rivera D, Aguayo A, Rodríguez W, Garza MT, Saracho CP et al. Trail Making Test: normative data for the Latin American Spanish speaking adult population. Neuro Rehabilitation. 2015;37(4):639-61. https://doi.org/10.3233/NRE-151284
• 25 Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323-9. https://doi.org/10.1093/geronj/37.3.323
• 26 Surace E, Cohen G, Martinetto H. ChremMendez P, Martín E, Smyth E et al. Latin American experience with Alzheimer's disease cerebrospinal fluid biomarkers. J Am Geriatr Soc. 2013 Jul;61(7):1229-31. https://doi.org/10.1111/jgs.12352.
• 27 Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009 Dec;66(12):1557-62. https://doi.org/10.1001/archneurol.2009.279
• 28 Piguet O, Halliday GM, Creasey H, Broe GA, Kril JJ. Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. Int Psychogeriatr. 2009 Aug;21(4):688-95. https://doi.org/10.1017/S1041610209009454
• 29 Hodges JR, Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications. Neuropsychologia. 1995 Apr;33(4):441-59. https://doi.org/10.1016/0028-3932(94)00127-B